A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 72 (planned)
- Started
- Oct 13, 2026
- Main results expected
- Jan 31, 2031
- Fully finished
- Jan 31, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Measured over: Up to 224 weeks
Duration of TEAEs and SAEs
Measured over: Up to 224 weeks
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) by severity
Measured over: Up to 224 weeks
Number of participants with adverse events or serious adverse events leading to dose modification or study intervention discontinuation
Measured over: Up to 224 weeks
Number of participants with clinically significant changes in vital signs, laboratory parameters, cardiac function, and Eastern Cooperative Oncology Group (ECOG) performance status changes
Measured over: Up to 224 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07843641 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC